| P50 | author | Baoan Chen | Q105978745 |
| P2093 | author name string | Jos L Campbell | |
| | Runzhe Chen | |
| P2860 | cites work | Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. | Q39424810 |
| | A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation. | Q40413839 |
| | The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse | Q42923393 |
| | Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. | Q42961857 |
| | Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia | Q43457128 |
| | Interleukin-2 priming chemotherapy: a strategy to improve the remission of refractory/relapsed T cell acute lymphoblastic leukemia | Q43591776 |
| | Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis | Q43690436 |
| | Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation | Q44017116 |
| | Level of vascular endothelial growth factor predicts both relapse and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. | Q44018845 |
| | Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation | Q44318605 |
| | Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia | Q44505579 |
| | Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. | Q44848328 |
| | Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia | Q45088616 |
| | Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation | Q45179458 |
| | Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. | Q45735200 |
| | Effects of aGVHD and cGVHD according to relapse status on survival rate in patients with acute lymphocytic leukemia. | Q45931931 |
| | Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia | Q46341511 |
| | Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation | Q47435716 |
| | Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia | Q48013821 |
| | A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor | Q48763487 |
| | Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia | Q27851831 |
| | Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia | Q27852997 |
| | Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival | Q33816659 |
| | Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia. | Q33831349 |
| | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr | Q34044024 |
| | Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. | Q34049208 |
| | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio | Q34202277 |
| | Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. | Q34380489 |
| | Targeting signaling pathways in acute lymphoblastic leukemia: new insights | Q34390600 |
| | NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic ma | Q35605318 |
| | Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation | Q35731623 |
| | Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia | Q35750934 |
| | Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation | Q35752737 |
| | Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. | Q35965199 |
| | Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia | Q36100435 |
| | Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol | Q36366644 |
| | Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment | Q36797787 |
| | Relapse after allogeneic hematopoietic cell therapy. | Q36799799 |
| | Current status of haploidentical stem cell transplantation for leukemia. | Q37088557 |
| | CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation | Q37100764 |
| | Allogeneic hematopoietic stem cell transplantation for patients with acute leukemia | Q37118214 |
| | Donor lymphocyte infusions: the long and winding road: how should it be traveled? | Q37246638 |
| | Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse | Q37369407 |
| | Treatment and management of graft-versus-host disease: improving response and survival | Q37371836 |
| | Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival | Q37601706 |
| | Antibody therapy for pediatric leukemia. | Q37725578 |
| | Transplants for leukemia in relapse: when is the best time? | Q37962789 |
| | Current and future management of Ph/BCR-ABL positive ALL. | Q38194585 |
| | Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions | Q38207595 |
| | Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia | Q38681322 |
| | Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R. | Q38995180 |
| | MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene | Q39093042 |
| | Prognostic factors for outcomes of pediatric patients with refractory or relapsed acute leukemia undergoing allogeneic progenitor cell transplantation. | Q50568189 |
| | Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia. | Q50701884 |
| | Factors affecting the outcome of stem cell transplantation from unrelated donors for childhood acute lymphoblastic leukemia in third remission. | Q50773044 |
| | Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. | Q51735777 |
| | Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. | Q52892334 |
| | High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. | Q53152680 |
| | Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. | Q53644897 |
| | Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia--rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation. | Q54218063 |
| | Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study. | Q54342246 |
| | Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Q54424684 |
| | Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. | Q54639337 |
| | Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia | Q57918084 |
| | Allogeneic Stem Cell Transplantation in First Complete Remission Enhances Graft-versus-Leukemia Effect in Adults with Acute Lymphoblastic Leukemia: Antileukemic Activity of Chronic Graft-versus-Host Disease | Q62022718 |
| | Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia | Q62128235 |
| | Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival | Q73089005 |
| | Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome | Q73719654 |
| | Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation | Q73850150 |
| | Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease | Q76319383 |
| | Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience | Q79557478 |
| | KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy | Q79973289 |
| | Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? | Q87094752 |
| | Prognostic index for relapsed acute leukemia after allogeneic stem cell transplant | Q87331165 |
| | Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation | Q87613803 |
| | Efficacy of prophylactic additional cranial irradiation and intrathecal chemotherapy for the prevention of CNS relapse after allogeneic hematopoietic SCT for childhood ALL | Q87847226 |
| | Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity | Q87939734 |
| | The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation | Q88084663 |
| | Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia | Q88206170 |
| | [Control of graft-versus-host disease] | Q95562465 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lymphoblastic leukemia | Q18553852 |
| P304 | page(s) | 405-412 | |
| P577 | publication date | 2015-02-10 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation | |
| P478 | volume | 8 | |